Beckman Coulter partners with South West London Pathology to reduce the impact of sepsis

Link-up will see implementation of DxH 900 haematology analysers and Early Sepsis Indicator

South West London Pathology will use new heamatology analysers to detect sepsis

  • Installation enables SWLP laboratories to provide a single, integrated pathology service to more than 3.5 million people across South West London via three hospitals, 200 GP practices, and 30 community healthcare sites
  • Demonstrating an industry-leading 93% first-pass yield, the DxH 900 reduces the number of manual slide reviews, helping to generate reportable results as quickly as possible
  • The DxH 900 also features the Early Sepsis Indicator , the only CE-Mark and FDA-cleared hematologic biomarker that aids the diagnosis of sepsis in adult patients

South West London Pathology (SWLP) has implemented Beckman Coulter’s DxH 900 haematology analysers and the Early Sepsis Indicator across its network.

The award-winning NHS pathology partnership was set up by St George’s University Hospitals NHS Foundation Trust, Croydon Health Services NHS Trust, and Kingston Hospital NHS Foundation Trust.

And the installation enables SWLP laboratories to provide a single, integrated pathology service to more than 3.5 million people across South West London via three hospitals, 200 GP practices, and 30 community healthcare sites.

The analysers enable clinical laboratories to perform complete bloodcount and white blood cell differential tests.

Beckman Coulter’s DxH 900 and Early Sepsis Indicator will enable clinical teams to save lives through earlier detection of the killer infection

Demonstrating an industry-leading 93% first-pass yield, the DxH 900 reduces the number of manual slide reviews, helping to generate reportable results as quickly as possible.

In addition, it features the Early Sepsis Indicator , the only CE-marked and FDA-cleared haematologic biomarker that aids the diagnosis of sepsis in adult patients.

“Emergency departments across our network see 370,000 patients a year. And, with conditions like sepsis becoming more and more prevalent, it is mission critical to have the tools and technology to identify, diagnose, and begin treatment as early as possible ,” said Simon Brewer, managing director at South West London Pathology.

“We believe that Beckman Coulter’s DxH 900 and Early Sepsis Indicator will help us detect, and the clinical teams manage, sepsis more effectively.”

Peter Soltani, senior vice president and general manager of the haematology business unit at Beckman Coulter, added: “Our partners count on us to provide a broad menu of solutions that impact the treatment of the most-prevalent and costly health conditions. And, in cases like sepsis, where every minute counts, having a biomarker included as part of a routine CBC blood test enables detection earlier in the critical care pathway, which can make a huge difference.”

Companies